For decades, inflammation was thought to resolve passively — once the inciting stimulus disappeared, immune cells simply dissipated. That model collapsed in the early 2000s when Charles Serhan’s laboratory at Harvard discovered that the resolution of inflammation is an active, programmed biochemical process driven by a family of lipid mediators enzymatically derived from EPA and DHA. These molecules — resolvins, protectins, and maresins — don’t merely block inflammatory signaling. They actively instruct immune cells to stop infiltrating, clear apoptotic neutrophils, and return tissue to homeostasis. This reframes the entire clinical rationale for omega-3 supplementation.
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are a class of endogenous lipid signaling molecules biosynthesized from the omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The major families include the E-series resolvins (derived from EPA), the D-series resolvins, protectins, and maresins (derived from DHA). They were first identified by Serhan and colleagues in resolving inflammatory exudates and characterized through lipidomic profiling using LC-MS/MS.[1]
Unlike traditional anti-inflammatory agents such as NSAIDs or corticosteroids — which inhibit the production of pro-inflammatory mediators — SPMs act as agonists at specific G-protein coupled receptors to actively promote the resolution phase of inflammation. They are produced in nanogram to picogram quantities and exert potent biological effects at low concentrations.[2]
How Resolvin Biosynthesis from EPA and DHA Works
Substrate Mobilization: Resolution begins when EPA and DHA are released from membrane phospholipids by phospholipase A2. These free fatty acids then become substrates for sequential oxygenation by lipoxygenase (LOX) and cyclooxygenase-2 (COX-2) enzymes — the same enzymes involved in pro-inflammatory eicosanoid production, but operating in a transcellular biosynthetic pathway during the resolution phase.[1]
E-Series Resolvin Synthesis: EPA is converted to 18R-hydroxyeicosapentaenoic acid (18R-HEPE), often via aspirin-acetylated COX-2 or cytochrome P450 enzymes. 18R-HEPE is then transformed by 5-LOX in leukocytes to produce resolvin E1 (RvE1) and resolvin E2 (RvE2). RvE1 signals through the ChemR23 (ERV1) receptor on neutrophils, dendritic cells, and macrophages to limit neutrophil infiltration and enhance macrophage clearance of apoptotic cells.[2]
D-Series Resolvin Synthesis: DHA is converted by 15-LOX to 17S-hydroperoxy-DHA, which is then transformed by 5-LOX into resolvins D1 through D6. RvD1 signals through GPR32 and ALX/FPR2 receptors, while RvD2 acts on GPR18. These receptors are expressed on neutrophils, monocytes, and tissue macrophages, where SPM binding triggers a phenotypic shift toward resolution.[3]
Protectin Biosynthesis: DHA is also converted via 15-LOX to 17S-hydroperoxy-DHA, which is further transformed into protectin D1 (PD1/NPD1 when produced in neural tissue). Protectins are particularly enriched in the brain and retina, where DHA concentrations are highest, and play roles in neuroprotection and resolution of ocular inflammation.[1]
Maresin Biosynthesis: Macrophages convert DHA via 12-LOX into 13S,14S-epoxy-maresin, which is then transformed into maresin 1 (MaR1). The name derives from “macrophage mediator in resolving inflammation.” Maresins promote tissue regeneration, reduce pain, and stimulate efferocytosis — the clearance of apoptotic neutrophils by macrophages, a critical step in resolution.[4]
Clinical Evidence
Class Switching of Lipid Mediators: A landmark observation in human studies is the temporal switch from pro-inflammatory leukotrienes and prostaglandins to SPMs as inflammation resolves. This switch is delayed or impaired in chronic inflammatory states, providing a mechanistic basis for diseases of failed resolution including atherosclerosis, periodontitis, and chronic obstructive pulmonary disease.[2]
EPA/DHA Supplementation Raises SPM Levels: A randomized controlled trial in healthy adults demonstrated that oral supplementation with EPA and DHA produces dose-dependent increases in plasma levels of 18-HEPE, 17-HDHA, and 14-HDHA — the immediate precursors of E-series resolvins, D-series resolvins, and maresins respectively. SPM precursor levels rose within hours of ingestion and were sustained with continued supplementation.[5]
Cardiovascular and Atherosclerosis Research: Resolvin D1 has been shown in preclinical models to stabilize atherosclerotic plaques by promoting macrophage efferocytosis of apoptotic cells within the lesion. Impaired resolution — rather than excessive inflammation alone — appears to drive the transition from stable to vulnerable plaque morphology.[3]
Resolution in Infection: SPMs enhance bacterial clearance while simultaneously reducing inflammatory tissue damage. RvD2 administration in murine sepsis models improved survival and bacterial clearance compared to antibiotics alone, suggesting that promoting resolution is mechanistically distinct from — and complementary to — immunosuppression.[4]
Safety Profile
SPMs themselves are endogenous molecules produced in extremely low concentrations, and isolated synthetic SPMs are currently investigational rather than clinically available. The practical clinical exposure to SPM biology comes through EPA and DHA supplementation, which has been studied extensively. High-purity EPA/DHA preparations have been evaluated in large cardiovascular outcome trials at doses up to 4 grams daily with well-characterized safety profiles, with the main considerations being mild gastrointestinal effects and a modest dose-dependent increase in atrial fibrillation observed in some trials at high doses.
Importantly, aspirin acetylates COX-2 to redirect EPA and DHA metabolism toward aspirin-triggered SPMs (AT-resolvins, AT-protectins), which are epimers of the native SPMs with similar or enhanced bioactivity and resistance to enzymatic inactivation. This provides a mechanistic explanation for some of the anti-inflammatory benefits of low-dose aspirin that extend beyond platelet inhibition.[1]
SPMs vs Traditional Anti-Inflammatory Approaches
Versus NSAIDs: Non-steroidal anti-inflammatory drugs inhibit COX enzymes and block production of prostaglandins. However, COX-2 inhibition also blocks the substrate channeling that generates resolvin precursors, which may paradoxically delay resolution. SPMs achieve anti-inflammatory effects without suppressing host defense or impairing resolution biology.
Versus Corticosteroids: Glucocorticoids broadly suppress immune cell function and gene expression. They reduce inflammation but also impair wound healing, increase infection risk, and do not actively promote return to homeostasis. SPMs are immunoresolvent rather than immunosuppressive — they enhance bacterial clearance while limiting tissue damage.[2]
Versus Fish Oil as Anti-Inflammatory: The traditional framing of EPA and DHA as anti-inflammatory by virtue of competing with arachidonic acid is incomplete. The SPM paradigm reframes omega-3 fatty acids as substrates for active resolution programs. This explains why EPA/DHA effects are often most pronounced in conditions characterized by failed resolution — including chronic periodontitis, inflammatory bowel disease, and cardiovascular disease — rather than acute inflammation.[3]
Versus Biologics: Monoclonal antibodies targeting TNF-α, IL-6, or IL-17 block specific cytokine signaling but do not engage resolution biology. Combination approaches that pair targeted cytokine inhibition with strategies to promote resolution — including optimized omega-3 status — represent an emerging research direction in chronic inflammatory disease management.[5]
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Levy BD. “Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.” Journal of Clinical Investigation. 2018;128(7):2657-2669.
- Bäck M, Yurdagul A, Tabas I, Öörni K, Kovanen PT. “Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities.” Nature Reviews Cardiology. 2019;16(7):389-406.
- Chiang N, Serhan CN. “Specialized pro-resolving mediator network: an update on production and actions.” Essays in Biochemistry. 2020;64(3):443-462.
- Souza PR, Marques RM, Gomez EA, et al. “Enriched marine oil supplements increase peripheral blood specialized pro-resolving mediators concentrations and reprogram host immune responses.” Circulation Research. 2020;126(1):75-90.
